Bora-Pharmaceuticals-Header Bora-Pharmaceuticals-Header

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Lead Product(s): IRL201104

            Therapeutic Area: Gastroenterology Product Name: ‘1104

            Highest Development Status: Phase I Product Type: Peptide

            Partner/Sponsor/Collaborator: Revolo Biotherapeutics

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement April 15, 2021

            Details:

            CordenPharma will Provide manufacturing support for Revolo Bio’s first-in-class peptide and immune system resetting drug product, ‘1104, for its upcoming Phase 2 clinical trials in patients with eosinophilic esophagitis (EoE) and allergic disease.